Copyright
©The Author(s) 2017.
World J Gastroenterol. Jan 21, 2017; 23(3): 540-546
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.540
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.540
Table 2 Prognostic factors for overall survival
| Factor | No. | Median survival t/mo | Log-rank |
| Cycle(s) | 0.013 | ||
| 1-3 | 26 | 16.1 | |
| 4 | 50 | 35.5 | |
| Stage | 0.037 | ||
| II-III | 48 | 36.1 | |
| IV | 28 | 14.9 | |
| Gender | 0.093 | ||
| Male | 63 | 17.3 | |
| Female | 13 | 35.5 | |
| Age | 0.708 | ||
| < 65 yr | 58 | 23.4 | |
| ≥ 65 yr | 18 | 27.0 | |
| Radiation | 0.626 | ||
| CF | 60 | 23.4 | |
| LCAF | 16 | 28.5 |
- Citation: Zhu HT, Ai DS, Tang HR, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y, Zhang Z, Xia Y, Guo XM, Jiang GL, Zhao KL. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma. World J Gastroenterol 2017; 23(3): 540-546
- URL: https://www.wjgnet.com/1007-9327/full/v23/i3/540.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i3.540